Rewiring the Brain… Dr. Peter Vanderklish, Chief Scientific Officer, Spinogenix
Companies To Watch: Spinogenix
Enhancing Neurodegenerative Care: Dialogue Exchange with Stella Sarraf of Spinogenix
To Reverse Aging’s Clock, Adjust the Cell’s Machinery
FDA Clears Phase 1/2 Clinical Trial for Spinogenix’s ALS Treatment SPG302
Spinogenix Announces FDA Clearance of IND Application Novel Therapy for the Treatment of ALS
First Synaptic Regenerative Therapy for Schizophrenia Under Investigation
Synapse-restoring pill set for human trials as novel schizophrenia treatment
Early Clinical Development of Synapse-Focused Agent SPG302 for Alzheimer Disease
World-first MND drug trial offers hope to those living with the disorder
